| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5883004 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 7 Pages |
Abstract
Although high-risk cytogenetic findings negatively affect progression-free survival and overall survival, 28% of cytogenetic high-risk patients experienced long survival, provided that lenalidomide therapy was not discontinued, thus pointing to the role of maintenance therapy in this subset of patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Renato Zambello, Laura Bonaldi, Tamara Berno, Annalisa Martines, Erica Sechettin, Elena De March, Antonio Branca, Albana Lico, Claudia Minotto, Chiara Briani, Carmela Gurrieri, Francesca Temporin, Claudia Battistutta, Francesco Piazza, Monica Cavraro,